Answers are grounded in this paper and cite their sources.
Cross-sectional study finds salivary HER2 correlates with breast cancer diagnosis, suggesting a noninvasive tool.
Background: Breast cancer constitutes a significant proportion of malignancies among the female population, accounting for approximately 25% of all cancer cases on a global scale. Human epidermal growth factor receptor-2 (HER2) is the more reliable marker in breast cancer diagnosis. Objective: This study investigates the potential of soluble salivary HER2 in breast cancer diagnosis and explores its correlation with demographic and hormonal factors. Materials and Methods: A total of 45 subjects were selected and divided into three groups: Group A: healthy patients ( n = 15), Group B: HER2-negative breast cancer patients ( n = 15), and Group C: HER2-positive breast cancer patients ( n = 15). Patients’ saliva was collected, and assessment of salivary soluble HER2 was performed by using an enzyme-linked immunosorbent assay kit. Results: Salivary HER2 levels were 32.3 pg/ml in healthy group, 43.2 pg/ml in HER2-negative group, and 147.8 pg/ml in HER2-positive group. On evaluating the risk factors associated with the salivary HER2 levels, increased age ( P = 0.007), positive family history ( P = 0.006), patients with the habit of tobacco chewing ( P = 0.001), and patients with no breastfeeding history ( P = 0.001) showed a statistically significant result. Conclusion: Salivary HER2 levels were higher in both HER2-positive and -negative breast cancer groups compared to controls, indicating its potential as a noninvasive diagnostic tool for breast cancer screening.
No takes yet. Share an insight, caveat, or question.
Arthisri et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: